Lowest-Rated StocksLowest-RatedNASDAQ:CTMX CytomX Therapeutics (CTMX) Stock Forecast, Price & News $1.73 +0.05 (+2.98%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$1.68▼$1.7350-Day Range$1.48▼$1.9252-Week Range$1.17▼$3.02Volume156,651 shsAverage Volume463,519 shsMarket Capitalization$114.77 millionP/E RatioN/ADividend YieldN/APrice Target$3.17 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability CytomX Therapeutics MarketRank™ ForecastAnalyst RatingHold2.09 Rating ScoreUpside/Downside83.3% Upside$3.17 Price TargetShort InterestHealthy3.28% of Float Sold ShortDividend StrengthN/ASustainability-0.74Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$30,332 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.62) to ($0.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.27 out of 5 starsMedical Sector266th out of 983 stocksPharmaceutical Preparations Industry117th out of 486 stocks 3.0 Analyst's Opinion Consensus RatingCytomX Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.09, and is based on 2 buy ratings, 8 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.17, CytomX Therapeutics has a forecasted upside of 83.3% from its current price of $1.73.Amount of Analyst CoverageCytomX Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.28% of the float of CytomX Therapeutics has been sold short.Short Interest Ratio / Days to CoverCytomX Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CytomX Therapeutics has recently decreased by 13.41%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCytomX Therapeutics does not currently pay a dividend.Dividend GrowthCytomX Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCytomX Therapeutics has received a 74.21% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health", "Basic medical research services", and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for CytomX Therapeutics is -0.74. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for CytomX Therapeutics this week, compared to 3 articles on an average week.Search Interest2 people have searched for CTMX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CytomX Therapeutics insiders have sold 291.38% more of their company's stock than they have bought. Specifically, they have bought $7,750.00 in company stock and sold $30,332.00 in company stock.Percentage Held by InsidersOnly 6.50% of the stock of CytomX Therapeutics is held by insiders.Percentage Held by Institutions70.14% of the stock of CytomX Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for CytomX Therapeutics are expected to decrease in the coming year, from ($0.62) to ($0.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CytomX Therapeutics is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CytomX Therapeutics is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About CytomX Therapeutics (NASDAQ:CTMX) StockCytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.Read More Receive CTMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CTMX Stock News HeadlinesJune 1, 2023 | finance.yahoo.comCytomX Therapeutics to Present at the Jefferies Healthcare ConferenceMay 14, 2023 | americanbankingnews.comCytomX Therapeutics, Inc. to Post Q2 2023 Earnings of ($0.39) Per Share, Wedbush Forecasts (NASDAQ:CTMX)June 3, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 14, 2023 | americanbankingnews.comBrokers Set Expectations for CytomX Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:CTMX)May 12, 2023 | americanbankingnews.comStockNews.com Upgrades CytomX Therapeutics (NASDAQ:CTMX) to "Buy"May 12, 2023 | americanbankingnews.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $3.17 Consensus Target Price from AnalystsMay 11, 2023 | finance.yahoo.comCytomX Therapeutics First Quarter 2023 Earnings: Beats ExpectationsMay 10, 2023 | finance.yahoo.comQ1 2023 CytomX Therapeutics Inc Earnings CallJune 3, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 10, 2023 | markets.businessinsider.comCytomX Therapeutics (CTMX) Receives a Hold from Mizuho SecuritiesMay 9, 2023 | finance.yahoo.comCytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 7, 2023 | americanbankingnews.comCytomX Therapeutics (CTMX) to Release Earnings on TuesdayMay 5, 2023 | finance.yahoo.comCytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Are Not Doing Enough For Some InvestorsMay 1, 2023 | finance.yahoo.comCytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023April 27, 2023 | finance.yahoo.comWill CytomX Therapeutics (CTMX) Report Negative Q1 Earnings? What You Should KnowApril 25, 2023 | finance.yahoo.comCytomX Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQApril 17, 2023 | americanbankingnews.comBrokerages Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $3.17April 13, 2023 | americanbankingnews.comHead to Head Comparison: CytomX Therapeutics (NASDAQ:CTMX) & Stoke Therapeutics (NASDAQ:STOK)April 3, 2023 | americanbankingnews.comCytomX Therapeutics (NASDAQ:CTMX) Lifted to "Hold" at StockNews.comApril 1, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for CytomX Therapeutics, Inc. (NASDAQ:CTMX) Increased by AnalystApril 1, 2023 | americanbankingnews.comCytomX Therapeutics, Inc. Expected to Earn Q1 2023 Earnings of ($0.33) Per Share (NASDAQ:CTMX)March 31, 2023 | americanbankingnews.comCytomX Therapeutics' (CTMX) "Neutral" Rating Reiterated at WedbushMarch 31, 2023 | americanbankingnews.comEquities Analysts Set Expectations for CytomX Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:CTMX)March 30, 2023 | finance.yahoo.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2022 Earnings Call TranscriptMarch 30, 2023 | americanbankingnews.comBrokers Issue Forecasts for CytomX Therapeutics, Inc.'s Q1 2023 Earnings (NASDAQ:CTMX)March 30, 2023 | americanbankingnews.comCytomX Therapeutics (NASDAQ:CTMX) PT Lowered to $2.00March 29, 2023 | seekingalpha.comCytomX Therapeutics, Inc. (CTMX) Q4 2022 Earnings Call TranscriptSee More Headlines CTMX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTMX Company Calendar Last Earnings3/27/2023Today6/03/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CTMX CUSIPN/A CIK1501989 Webwww.cytomx.com Phone(605) 515-3185Fax650-351-0353Employees174Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.17 High Stock Price Forecast$8.00 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+83.3%Consensus RatingHold Rating Score (0-4)2.09 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-99,320,000.00 Net Margins-132.29% Pretax Margin-118.68% Return on Equity-666.28% Return on Assets-32.07% Debt Debt-to-Equity RatioN/A Current Ratio1.40 Quick Ratio1.40 Sales & Book Value Annual Sales$53.16 million Price / Sales2.16 Cash FlowN/A Price / Cash FlowN/A Book Value($1.31) per share Price / Book-1.32Miscellaneous Outstanding Shares66,340,000Free Float62,027,000Market Cap$114.77 million OptionableOptionable Beta0.65 Key ExecutivesSean A. McCarthyChairman, President & Chief Executive OfficerChris OgdenChief Financial & Accounting OfficerMarcia P. BelvinChief Scientific Officer & Senior Vice PresidentLloyd A. RowlandSecretary, Compliance Officer & General CounselJeffrey LandauChief Business Officer, Senior VP & Head-StrategyKey CompetitorsCapricor TherapeuticsNASDAQ:CAPRReviva PharmaceuticalsNASDAQ:RVPHViveon Health AcquisitionNYSE:VHAQOncolytics BiotechNASDAQ:ONCYSeelos TherapeuticsNASDAQ:SEELView All CompetitorsInsiders & InstitutionsToroso Investments LLCSold 27,794 shares on 5/23/2023Ownership: 0.480%Geode Capital Management LLCBought 39,233 shares on 5/16/2023Ownership: 0.968%State Street CorpBought 43,500 shares on 5/16/2023Ownership: 0.403%Squarepoint Ops LLCBought 48,856 shares on 5/16/2023Ownership: 0.074%Susquehanna International Group LLPBought 28,000 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions CTMX Stock - Frequently Asked Questions Should I buy or sell CytomX Therapeutics stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 1 sell rating, 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CTMX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTMX, but not buy additional shares or sell existing shares. View CTMX analyst ratings or view top-rated stocks. What is CytomX Therapeutics' stock price forecast for 2023? 11 Wall Street research analysts have issued 1 year price targets for CytomX Therapeutics' stock. Their CTMX share price forecasts range from $1.50 to $8.00. On average, they predict the company's share price to reach $3.17 in the next year. This suggests a possible upside of 83.3% from the stock's current price. View analysts price targets for CTMX or view top-rated stocks among Wall Street analysts. How have CTMX shares performed in 2023? CytomX Therapeutics' stock was trading at $1.60 at the start of the year. Since then, CTMX stock has increased by 8.1% and is now trading at $1.73. View the best growth stocks for 2023 here. Are investors shorting CytomX Therapeutics? CytomX Therapeutics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 2,130,000 shares, a decrease of 13.4% from the April 30th total of 2,460,000 shares. Based on an average daily trading volume, of 758,700 shares, the short-interest ratio is presently 2.8 days. Approximately 3.3% of the shares of the stock are short sold. View CytomX Therapeutics' Short Interest. When is CytomX Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our CTMX earnings forecast. How were CytomX Therapeutics' earnings last quarter? CytomX Therapeutics, Inc. (NASDAQ:CTMX) posted its quarterly earnings data on Monday, March, 27th. The biotechnology company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.21. The biotechnology company had revenue of $0.95 million for the quarter, compared to analyst estimates of $17.71 million. CytomX Therapeutics had a negative net margin of 132.29% and a negative trailing twelve-month return on equity of 666.28%. What ETFs hold CytomX Therapeutics' stock? ETFs with the largest weight of CytomX Therapeutics (NASDAQ:CTMX) stock in their portfolio include Formidable ETF (FORH) and Invesco Nasdaq Future Gen 200 ETF (QQQS). What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO? 12 employees have rated CytomX Therapeutics Chief Executive Officer Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among the company's employees. 80.0% of employees surveyed would recommend working at CytomX Therapeutics to a friend. What other stocks do shareholders of CytomX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX). What is CytomX Therapeutics' stock symbol? CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX." Who are CytomX Therapeutics' major shareholders? CytomX Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.69%), Renaissance Technologies LLC (1.28%), FMR LLC (1.06%), Assenagon Asset Management S.A. (1.01%), Geode Capital Management LLC (0.97%) and Two Sigma Advisers LP (0.78%). Insiders that own company stock include Amy C Peterson, Carlos Campoy, Christopher Ogden, Elaine V Jones, Jeffrey B Landau, Lloyd A Rowland and Sean A Mccarthy. View institutional ownership trends. How do I buy shares of CytomX Therapeutics? Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CytomX Therapeutics' stock price today? One share of CTMX stock can currently be purchased for approximately $1.73. How much money does CytomX Therapeutics make? CytomX Therapeutics (NASDAQ:CTMX) has a market capitalization of $114.77 million and generates $53.16 million in revenue each year. The biotechnology company earns $-99,320,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. How many employees does CytomX Therapeutics have? The company employs 174 workers across the globe. How can I contact CytomX Therapeutics? CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytomx.com. The biotechnology company can be reached via phone at (605) 515-3185, via email at ckeenan@cytomx.com, or via fax at 650-351-0353. This page (NASDAQ:CTMX) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.